Skip to content

Clinical application of fullerene repair moisturizing cream in prevention of acute radiation dermatitis

Clinical application of fullerene repair moisturizing cream in prevention of acute radiation dermatitis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079800
Enrollment
Unknown
Registered
2024-01-12
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute radiation dermatitis

Interventions

Experimental group:Fullerene repair moisturizer
Control group:FORRAD

Sponsors

The Second Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age >18 years old and =75 years old; (2) Patients with breast cancer or head and neck tumors clearly diagnosed by pathology; (3) Patients undergoing radiation therapy for the first time; (4) KPS score =70, expected survival >6 months; (5) radiotherapy for at least 4 weeks; (6) Before radiotherapy, white blood cells =4*10^9/L, hemoglobin =90g/L, platelets =80*10^9/L; (7) Patients have clear consciousness and can communicate effectively; (8) The patient voluntarily participates with informed consent.

Exclusion criteria

Exclusion criteria: (1) People with mental symptoms; (2) Patients with other skin diseases at the site of radiotherapy; (3) Combined with organ dysfunction, such as serious heart failure, kidney failure, etc.;

Design outcomes

Primary

MeasureTime frame
Incidence of acute radiation dermatitis at all levels;Minimum cumulative dose for all levels of acute radiation dermatitis;

Secondary

MeasureTime frame
Skindex-16;Pain;

Countries

China

Contacts

Public ContactJinli Guo

The Second Hospital of Shanxi Medical University

gjlgbd@126.com+86 135 4639 5590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026